Drug Trial Radar · NCT06545929
Study of Sunobinop on Craving in Alcohol Use Disorder
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jan 28, 2025
Primary completion
Jul 14, 2025
Study completion Jul 14, 2025
Sponsor
- Lead sponsor
- Knoa Pharma LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Imbrium Therapeutics
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol craving in subjects with moderate to severe alcohol use disorder and these subjects are seeking treatment.
Conditions
- Alcohol Use Disorder
Interventions
SunobinopDrug
1 tablet taken orally at bedtime
Placebo to match sunobinopDrug
1 tablet taken orally at bedtime
Primary outcomes
What the sponsor says the trial is designed to measure.
- Alcohol Urge Questionnaire (AUQ)Time frame: Day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ohio Clinical Trials
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.